For the first time, advanced prostate cancer has been treated based on the genomic makeup of the cancer, delaying disease progression for patients with a treatment-resistant form of prostate cancer.
Northwestern Medicine experts discuss the phenomenon of “caution fatigue,” where people may find it difficult to stay on high-risk alert after weeks of social distancing and isolation to stop the spread of COVID-19.
A novel drug called luspatercept may reduce blood transfusion burden for patients with transfusion-dependent beta-thalassemia, an inherited blood disorder.
A newly developed high-resolution brain mapping technology exceeds the lifespans of current platforms and may enhance how brain function is measured and how efficiently neurological diseases are diagnosed and treated.
Many individuals in the highest risk category for COVID-19 because of multiple chronic health conditions didn’t think the disease would affect them and reported not changing their behavior at the beginning of Chicago’s outbreak, according to a new study.
Northwestern Medicine cardiovascular experts discuss how racial disparities, including lower socioeconomic status and pre-existing cardiovascular conditions, can lead African-Americans to be at higher risk for contracting and dying from COVID-19.
A novel heart failure drug called sacubitril-valsartan reduced the risk of hospitalizations for heart failure and death from cardiovascular causes more in women than in men, according to a study published in Circulation.
Northwestern Medicine has enrolled its first participants in a new international clinical drug trial for COVID-19, testing remdesivir, a novel anti-viral drug developed to treat Ebola, and which has also shown antiviral activity in coronaviruses.
A new method of delivering radiation during whole brain radiotherapy could reduce neurotoxicity without compromising effectiveness, according to a new study.
A special COVID-19 testing team has been put in place at Northwestern, with the goal of at least quadrupling the number of tests processed at Northwestern Medicine hospitals — from about 90 per day to more than 350 per day — and in the process, greatly reducing test result turnaround times.
Notifications